latest update:
[TrialBase DB]

trial summary · NCT07755956

Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis

A Phase Ia Clinical Trial to Compare Pharmacokinetics, Pharmacodynamics, Safety and Preliminary Efficacy of HHK001 Versus Enantone in Patients With Endometriosis

Trial record from the TrialBase DB dataset, status RECRUITING, condition Endometriosis, sponsored by Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07755956phase PHASE1enrollment 20start 2026-10-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check how the body absorbs and responds to each medicine, monitor possible side effects and treatment benefits. Researchers will compare HHK001 to Enantone to test the advantages of its updated formulation.

Source record: https://clinicaltrials.gov/study/NCT07755956

Facts

registry idNCT07755956
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionEndometriosis
sponsorZhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
sponsor classINDUSTRY
enrollment20
start date2026-10-31
primary completion2027-03-31
completion2027-03-31
results postednot reported

Conditions

  • Endometriosis

Interventions

  • Leuprorelin Acetate
  • Leuprorelin Acetate 3.75mg Injection

Countries

  • China

Intervention types: DRUG

Work with this record